Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 11/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 11/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.32 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.32 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.32 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.32 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | AHCY | P23526 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9912314 | 0.87 | PIK3CD (0.32) | ACVRL1PIK3CD | |
| SCHEMBL14642542 | 0.84 | CSNK2A2 (0.36) | CSNK2A2CSNK2A1MTORRICTORRPTOR | |
| SCHEMBL13696400 | 0.79 | DOT1L (0.35) | — | |
| SCHEMBL9912317 | 0.79 | DOT1L (0.35) | — | |
| SCHEMBL14642529 | 0.77 | PIK3CD (0.37) | CSNK2A2CSNK2A1AXLMERTKACVRL1 | |
| SCHEMBL13532224 | 0.77 | CSNK2A2 (0.38) | CSNK2A2CSNK2A1AXLTYRO3MERTK | |
| SCHEMBL12388999 | 0.76 | CSNK2A2 (0.32) | CSNK2A2CSNK2A1 | |
| SCHEMBL9912329 | 0.75 | — | — | |
| SCHEMBL13519756 | 0.73 | ACVRL1 (0.36) | CSNK2A2CSNK2A1MTORRICTORRPTOR | |
| SCHEMBL7602186 | 0.73 | ACVRL1 (0.36) | CSNK2A2CSNK2A1ACVRL1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2009111653-A2 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | EIF2AK2, ZC3HAV1, MAVS | CSNK2A2 2105/4885CSNK2A1 1582/4885MTOR 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.